Urothelial Carcinoma Treatment Market Size

  • Report ID: 3912
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Urothelial Carcinoma Treatment Market Size

Urothelial Carcinoma Treatment Market size was valued at USD 1.47 billion in 2024 and is set to exceed USD 17.9 billion by 2037, expanding at over 21.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of urothelial carcinoma treatment is evaluated at USD 2.01 billion.

The growth of the market can be attributed to the increasing incidence of bladder cancer worldwide. Further, in terms of prevalence, bladder cancer ranks 10th around the globe. Men have nearly four times more chances than women to have bladder cancer.  Smoking poses the biggest risk for bladder cancer, as tobacco contains carcinogens, which are poisons, and are known to cause cancer. Long-term smoking causes your kidneys to filter these poisons into urine before they enter your bloodstream. According to estimates, there are more than 1 billion smokers globally. This number is projected to increase to 2 billion over the next 20 years.

In addition to these, factors that are believed to fuel the market growth of urothelial carcinoma treatment include the excessive use of analgesics. Analgesics are commonly known as "painkillers," which are used to treat a variety of pains, including headaches, injuries, and arthritis. Painkillers are safe however, they might have unfavorable side effects and difficulties if taken too regularly, for too long, or in very large doses. Further, urinary tract cancer and atherosclerosis disease are two additional severe consequences that can result from long-term strong painkiller usage. For instance, painkiller usage is the most typical cause of bladder cancer in women under the age of 50.


Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3912
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of urothelial carcinoma treatment is evaluated at USD 2.01 billion.

The urothelial carcinoma treatment market size was valued at USD 1.47 billion in 2024 and is set to exceed USD 17.9 billion by 2037, expanding at over 21.2% CAGR during the forecast period i.e., between 2025-2037. Raising funding for research and development to develop novel cancer therapies and the growing awareness about bladder diseases will boost the market growth.

North America industry is set to account for largest revenue share of 38% by 2037, attributed to increasing frequency of urothelial carcinoma cancer in the region.

The major players in the market are Pfizer, Inc., GlaxoSmithKline plc, Novartis AG, Dendreon Pharmaceuticals LLC, Sanofi SA, F. Hoffmann-La-Roche AG, UroGen Pharma Ltd, Koninklijke Philips N.V., Olympus Corporation, AstraZeneca PLC
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample